You are on page 1of 2

67870 Federal Register / Vol. 67, No.

216 / Thursday, November 7, 2002 / Notices

1002(a) authorizing the importation of DEPARTMENT OF JUSTICE Drug Schedule


such a substance, provide
manufacturers holding registrations for Drug Enforcement Administration Dextropropoxyphene, bulk (non- II
the bulk manufacture of the substance dosage forms) (9273).
an opportunity for a hearing. Manufacturer of Controlled Levo-Alphacetylmethadol (9648) .. II
Substances; Notice of Application Oxymorphone (9652) ................... II
Therefore, in accordance with Section Fentanyl (9801) ............................ II
1301.34 of Title 21, Code of Federal Pursuant to section 1301.33(a) of Title
Regulations (CFR), notice is hereby 21 of the Code of Federal Regulations
(CFR), this is notice that on May 21, The firm plans to manufacture small
given that on May 13, 2002, Chattem quantities of the listed controlled
Chemicals, Inc., 3801 St. Elmo Avenue, 2002, Aldrich Chemical Company Inc.,
dba Isotec, 3858 Benner Road, substances to produce standards for
Building 18, Chattanooga, Tennessee analytical laboratories.
37409, made application by renewal to Miamisburg, Ohio 45342–4304, made
application to the Drug Enforcement Any other such applicant and any
the Drug Enforcement Administration to
Administration (DEA) for registration as person who is presently registered with
be registered as an importer of
a bulk manufacturer of the basic classes DEA to manufacture such substances
methamphetamine (1105), a basic class
of controlled substances listed below: may file comments or objections to the
of controlled substance listed in issuance of the proposed registration.
Schedule II.
Drug Schedule Any such comments or objections
The firm plans to import the listed may be addressed, in quintuplicate, to
controlled substance to bulk Cathinone (1235) .......................... I
Methcathinone (1237) .................. I the Deputy Assistant Administrator,
manufacture controlled substance. Office of Diversion Control, Drug
N-Ethylamphetamine (1475) ........ I
Any manufacturer holding, or N,N-Dimethylamphetamine (1480) I Enforcement Administration, United
applying for, registration as a bulk Aminorex (1585) ........................... I States Department of Justice,
manufacturer of this basic class of Gamma hydroxybutyric acid I Washington, DC 20537, Attention: DEA
controlled substance may file written (2010). Federal Register Representative (CCR),
comments on or objections to the Methaqualone (2565) ................... I and must be filed no later than January
Lysergic acid dethylamide (7315) I 6, 2003.
application described above and may, at Tetrahydrocannabinols (7370) ..... I
the same time, file a written request for Mescaline (7381) .......................... I Dated: October 25, 2002.
a hearing on such application in 2,5-Dimethoxyamphetamine I Laura M. Nagel,
accordance with 21 CFR 1301.43 in (7396). Deputy Assistant Administrator, Office of
such form as prescribed by 21 CFR 3,4-Methylenedioxyamphetamine I Diversion Control, Drug Enforcement
1316.47. (7400). Administration.
3,4-Methylenedioxy-N- I
Any such comments, objections, or ethylamphetamine (7404). [FR Doc. 02–28314 Filed 11–6–02; 8:45 am]
requests for a hearing may be addressed, 3,4-Methylenedioxy-methamphet- I BILLING CODE 4410–09–M
in quintuplicate, to the Deputy Assistant amine (7405).
Administration, Office of Diversion 4-Methoxyamphetamine (7411) ... I
Control, Drug Enforcement Psilocybin (7437) .......................... I DEPARTMENT OF JUSTICE
Administration, United States Psilocyn (7438) ............................. I
Department of Justice, Washington, DC N-Ethyl-1-phenylcyclohexylamine I Drug Enforcement Administration
(7455).
20537, Attention: DEA Federal Register Dihydromorphine (9145) ............... I Manufacturer of Controlled
Representative (CCR), and must be filed Normorphine (9313) ..................... I Substances; Notice of Application
no later than (30 days from publication). Acetylmethadol (9601) ................. I
This procedure is to be conducted Alphacetylmethadol Except Levo- I Pursuant to section 1301.33(a) of Title
Alphacetylmethadol (9603). 21 of the Code of Federal Regulations
simultaneously with and independent
Normethadone (9635) .................. I
of the procedures described in 21 CFR (CFR), this is notice that on May 28,
3-Methylfentanyl (9813) ................ I
1301.34(b), (c), (d), (e), and (f). As noted Amphetamine (1100) .................... II 2002, Abbott Laboratories, DBA Knoll
in a previous notice at 40 FR 43745–46 Methamphetamine (1105) ............ II Pharmaceutical Company, 30 North
(September 23, 1975), all applicants for Methylphenidate (1724) ................ II Jefferson Road, Whippany, New Jersey,
registration to import basic class of any Amobarbital (2125) ....................... II 07981, made application by renewal to
controlled substance in Schedule I or II Pentobarbital (2270) ..................... II the Drug Enforcement Administration
are and will continue to be required to Secobarbital (2315) ...................... II (DEA) for registration as a bulk
1-Phenylcyclohexylamine (7460) II manufacturer of the basic classes of
demonstrate to the Deputy Assistant
Phencyclidine (7471) .................... II controlled substances listed below:
Administrator, Office of Diversion Phenylacetone (8501) .................. II
Control, Drug Enforcement 1-Piperidinocyclohexane- II
Administration that the requirements Drug Schedule
carbonitrile (8603).
for such registration pursuant to 21 Codeine (9050) ............................. II Dihydromorphine (9145) ............... I
U.S.C. 958(a), 21 U.S.C. 823(a), and 21 Dihydrocodeine (9120) ................. II Hydromorphone (9150) ................ II
CFR 1301.34(a), (b), (c), (d), (e), and (f) Oxycodone (9143) ........................ II
are satisfied. Hydromorphone (9150) ................ II
Benzoylecgonine (9180) ............... II The firm plans to produce bulk
Dated: October 25, 2002. Ethylmorphine (9190) ................... II product and finished dosage units for
Laura M. Nagel, Hydrocodone (9193) ..................... II distribution to its customers.
Isomethadone (9226) ................... II
Deputy Assistant Administrator, Office of
Meperidine (9230) ........................ II
Any other such applicant and any
Diversion Control, Drug Enforcement person who is presently registered with
Meperidine intermediate-A (9232) II
Administration. DEA to manufacture such substances
Merperidine intermediate-B (9233) II
[FR Doc. 02–28312 Filed 11–6–02; 8:45 am] Methadone (9250) ........................ II may file comments or objections to the
BILLING CODE 4410–09–M Methadone intermediate (9254) ... II issuance of the proposed registration.

VerDate 0ct<09>2002 14:39 Nov 06, 2002 Jkt 200001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1
Federal Register / Vol. 67, No. 216 / Thursday, November 7, 2002 / Notices 67871

Any such comments or objections Administration, United States and a review of the company’s
may be addressed, in quintuplicate, to Department of Justice, Washington, DC background and history. Therefore,
the Deputy Assistant Administrator, 20537, Attention: DEA Federal Register pursuant to 21 U.S.C. 823 and 28 CFR
Office of Diversion Control, Drug Representative (CCR), and must be filed 0.100 and 0.104, the Deputy Assistant
Enforcement Administration, United no later than (30 days from publication). Administrator, Office of Diversion
States Department of Justice, This procedure is to be conducted Control, hereby orders that the
Washington, DC 20537, Attention: DEA simultaneously with and independent application submitted by the above firm
Federal Register Representative (CCR), of the procedures described in 21 CFR for registration as a bulk manufacturer
and must be filed no later than January 1301.34(b), (c), (d), (e), and (f). As noted of the basic class of controlled substance
6, 2003. in a previous notice at 40 FR 43745–46 listed above is granted.
Dated: October 25, 2002. (September 23, 1975), all applicants for Dated: October 25, 2002.
registration to import basic class of any Laura M. Nagel,
Laura M. Nagel,
controlled substance in Schedule I or II Deputy Assistant Administrator, Office of
Deputy Assistant Administrator, Office of
are and will continue to be required to Diversion Control, Drug Enforcement
Diversion Control, Drug Enforcement
Administration. demonstrate to the Deputy Assistant Administration.
Administrator, Office of Diversion [FR Doc. 02–28316 Filed 11–6–02; 8:45 am]
[FR Doc. 02–28315 Filed 11–6–02; 8:45 am]
Control, Drug Enforcement BILLING CODE 4410–09–M
BILLING CODE 4410–09–M
Administration that the requirements
for such registration pursuant to 21
DEPARTMENT OF JUSTICE U.S.C. 958(a), 21 U.S.C. 823(a), and 21 DEPARTMENT OF JUSTICE
CFR 1311.42(a), (b), (c), (d), (e), and (f)
Drug Enforcement Administration are satisfied. Drug Enforcement Administration
Dated: October 25, 2002.
Importation of Controlled Substances; Manufacturer of Controlled
Laura M. Nagel, Substances Notice of Registration
Notice of Application
Deputy Assistant Administrator, Office of
Pursuant to Section 1008 of the Diversion Control, Drug Enforcement By Notice dated April 11, 2002, and
Controlled Substances Import and Administration. published in the Federal Register on
Export Act (21 U.S.C. 958(i)), the [FR Doc. 02–28311 Filed 11–6–02; 8:45 am] April 26, 2002, (67 FR 20828),
Attorney General shall, prior to issuing BILLING CODE 4410–09–M Organichem Corporation, 33 Riverside
a registration under this Section to a Avenue, Rensselaer, New York 12144,
bulk manufacturer of a controlled made application by renewal to the
substance in Schedule I or II and prior DEPARTMENT OF JUSTICE Drug Enforcement Administration
to issuing a regulation under Section (DEA) to be registered as a bulk
1002(a) authorizing the importation of Drug Enforcement Administration manufacturer of the basic classes of
such a substance, provide controlled substances listed below:
Manufacturer of Controlled
manufacturers holding registrations for Substances; Notice of Registration Drug Schedule
the bulk manufacture of the substance
an opportunity for a hearing. By Notice dated April 11, 2002, and Amphetamine (1100) .................... II
Therefore, in accordance with Section published in the Federal Register on Pentobarbital (2270) ..................... II
1301.34 of Title 21, Code of Federal April 26, 2002, (67 FR 20828), Novartis Methylphenidate (1724) ................ II
Regulations (CFR), notice is hereby Pharmaceutical Corporation, 59 Route Meperidine (9230) ........................ II
given that on June 23, 2002, Noramco 10, East Hanover, New Jersey 07936,
Inc., 1440 Olympic Drive, Athens, made application by renewal to the The firm plans to manufacture bulk
Georgia 30601, made application by Drug Enforcement Administration products for distribution to its
renewal to the Drug Enforcement (DEA) to be registered as a bulk customers.
Administration to be registered as an manufacturer of methylphenidate No comments or objections have been
importer of phenylacetone (8501), a (1724), a basic class of controlled received. DEA has considered the
basic class of controlled substance listed substance listed in Schedule II. factors in Title 21, United States Code,
Schedule II. The firm plans to manufacture section 823(a) and determined that the
The firm plans to import finished product for distribution to its registration of Organichem Corporation
phenylacetone for the production of customers. to manufacture the listed controlled
amphetamine. DEA has considered the factors in substances is consistent with the public
Any manufacturer holding, or Title 21, United States Code, Section interest at this time. DEA has
applying for, registration as a bulk 823a and determined that the investigated Organichem Corporation to
manufacturer of this basic class of registration of Novartis Pharmaceutical ensure that the company’s registration is
controlled substance may file written Corporation to manufacture consistent with the public interest. The
comments on or objections to the methylphenidate is consistent with the investigation included inspection and
application described above and may, at public interest at this time. DEA has testing of the company’s physical
the same time, file a written request for investigated Novartis Pharmaceutical security systems, verification of the
a hearing on such application in Corporation on a regular basis to ensure company’s compliance with state and
accordance with 21 CFR 1301.43 in that the company’s continued local laws, and a review of the
such form as prescribed by 21 CFR registration is consistent with the public company’s background and history.
1316.47. interest. These investigations have Therefore, pursuant to 21 U.S.C. 823
Any such comments, objections, or included inspection and testing of the and 28 CFR 0.100 and 0.104, the Deputy
requests for a hearing may be addressed, company’s physical security systems, Assistant Administrator, Office of
in quintuplicate, to the Deputy Assistant audits of the company’s records, Diversion Control, hereby orders that
Administrator, Office of Diversion verification of the company’s the application submitted by the above
Control, Drug Enforcement compliance with state and local laws, firm for registration as a bulk

VerDate 0ct<31>2002 16:18 Nov 06, 2002 Jkt 200001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1